Core Viewpoint - The company, Berry Genomics (000710), focuses on the reproductive health sector, achieving significant commercial effects in the prenatal testing market while the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [1] Group 1 - The company plans to expand its complex genetic testing services into more areas, leveraging artificial intelligence applications and years of experience in third-generation sequencing technology [1] - The company aims to provide more health services directly to the consumer (C-end) by integrating clinical medical data in the future [1] - The recent changes in major shareholder equity do not impact the company's business development [1]

Core Viewpoint - The company is focusing on the reproductive health sector and aims to expand its business despite ongoing financial challenges and significant credit impairment losses [2]. Group 1: Business Focus and Strategy - The company has achieved good commercial effects in the prenatal testing market but recognizes that the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [2]. - The company plans to leverage artificial intelligence and its years of experience in third-generation sequencing technology to offer complex genetic testing services in more areas [2]. - Future plans include providing more health services directly to end consumers (C-end) by integrating clinical medical data [2]. Group 2: Shareholder and Control Issues - The company stated that the recent judicial auction of shares by major shareholders will not affect its business development [2].